Mylan Pharmaceuticals has issued a voluntary recall of one batch of its 100 units/mL insulin glargine injection pens due to the potential for missing labels, according to a press release from the ...

In addition, “the use of biosimilar insulin, which was first approved in 2015, increased from 2.6% in 2017 to 8.2% in 2020 of total insulin treatment visits,” while “the total number of ...

Lannett previously said that subject dosing has been completed in the pivotal clinical trial of Lannett/HEC's biosimilar insulin glargine and no serious adverse events were reported. The company ...

Mylan also makes the distinction that this isn’t the Semglee brand pen, but unbranded Insulin Glargine-yfgn pens. This covers batch No. BF21002895, expiration August 2023.

The researchers found that insulin glargine was the most frequently used insulin, accounting for approximately half of treatment visits (2020: 2.6 million of 4.9 million visits).

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...